| DC Field | Value | Language |
|---|
| dc.contributor.author | Kekeeva, Е. | - |
| dc.contributor.author | Andreeva, Yu. | - |
| dc.contributor.author | Tanas, A. | - |
| dc.contributor.author | Kalinkin, A. | - |
| dc.contributor.author | Dmitriev, V. | - |
| dc.date.accessioned | 2024-10-03T11:44:55Z | - |
| dc.date.available | 2024-10-03T11:44:55Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | HRD Testing of Ovarian Cancer in Routine Practice: What Are We DealingWith? / Е. Kekeeva, Yu. Andreeva, A. Tanas [et al.] // International Journal of Molecular Sciences. - 2023. - Vol.24, №13.-Art. 10497. - Doi: 10.3390/ijms241310497. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/63668 | - |
| dc.description.abstract | Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | medical genetics | ru |
| dc.subject | oncology | ru |
| dc.subject | ovarian cancer | ru |
| dc.subject | homologous recombination deficiency | ru |
| dc.subject | BRCA mutation | ru |
| dc.subject | genomic instability score | ru |
| dc.subject | tumor purity | ru |
| dc.subject | pathological response | ru |
| dc.title | HRD Testing of Ovarian Cancer in Routine Practice: What Are We DealingWith? | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
